Drug Profile
DW 167
Alternative Names: DW-167Latest Information Update: 15 Dec 2015
Price :
$50
*
At a glance
- Originator Dong Wha Pharmaceutical
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Skin cancer
Most Recent Events
- 15 Dec 2015 Phase II development for Skin cancer is ongoing in South Korea
- 10 Aug 2015 Phase II development for Skin cancer is ongoing in South Korea
- 15 Oct 2007 Phase-II clinical trials in Skin cancer in South Korea (unspecified route)